BioSpace News Archive

Viveve Medical, Inc., a medical technology company focused on women’s intimate health, reported financial results for the quarter ended September 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET, Nov 11, 2021.

Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, reported results for the third quarter ended September 30, 2021.

Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, announced that Adam Simpson, Chief Executive Officer of Icosavax, will participate in two upcoming investor conferences.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that members of its executive leadership team will participate in a virtual fireside chat discussion at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Nov. 18 at 8:30 a.m., EST.

Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to help prevent and better manage chronic diseases, reported financial results for the three months ending September 30, 2021 and provided a business update.

Celltrion Group announced today that the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59), a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

Alligator Bioscience AB and Aptevo Therapeutics announce preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and tumor antigen 5T4 will be presented in a poster at the Society of Immunotherapy Cancer’s 36th Annual Meeting, taking place virtually and in-person November 12- 14, 2021 in Washington D.C.

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced its financial and operating results for the three and nine months ended September 30, 2021.

Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced that data from approximately 7,000 plasma samples from more than 1,800 patients in the ADUHELM™ (aducanumab-avwa) Phase 3 clinical trials showed a statistically significant correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer’s disease.

Adaptive Biotechnologies Corporation announced that Palmetto GBA’s Molecular Diagnostics Program has finalized a local coverage determination which supports the Medicare coverage for clonoSEQ® to detect and monitor minimal residual disease in patients with B-cell acute lymphoblastic leukemia, multiple myeloma and chronic lymphocytic leukemia.